Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Horizon Therapeutics (NQ: HZNP ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Oct 5, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Horizon Therapeutics < Previous 1 2 ... 10 11 12 13 14 15 16 17 Next > Horizon Therapeutics plc Named One of the Fortune 100 Best Companies to Work For® April 11, 2022 From Horizon Therapeutics plc Via Business Wire Raytheon, Shell Lead Five Stocks Setting Up, Breaking Out From Strong Sectors April 09, 2022 Raytheon and Shell are just below buy points. They have good company. Via Investor's Business Daily Executives Sell More Than $262M Of 5 Stocks April 04, 2022 Although gold futures traded higher on Monday, there were a few notable insider trades. When insiders sell shares, it indicates their concern in the company’s prospects or... Via Benzinga New Analysis Finds UPLIZNA® (inebilizumab-cdon) Effective for People with Newly-Presenting Neuromyelitis Optica Spectrum Disorder (NMOSD) March 31, 2022 From Horizon Therapeutics plc Via Business Wire Earnings Scheduled For March 1, 2022 March 01, 2022 Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... Via Benzinga Horizon Therapeutics plc Named as One of the Best Workplaces in Ireland March 24, 2022 From Horizon Therapeutics plc Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022 March 15, 2022 Upgrades For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the... Via Benzinga Horizon Therapeutics Stock Shows Market Leadership; Earns 82 RS Rating March 08, 2022 Looking for the best stocks to buy? Horizon Therapeutics stock fits that bill with its Relative Strength Rating upgraded to 82. Via Investor's Business Daily Horizon Therapeutics Earnings Perspective: Return On Capital Employed March 04, 2022 Pulled from Benzinga Pro data, Horizon Therapeutics (NASDAQ:HZNP) posted Q4 earnings of $173.18 million, an increase from Q3 of 46.97%. Sales dropped to $1.01 billion, a 2.22%... Via Benzinga Horizon Therapeutics' Q4 Earnings Beat Expectation As Tepezza, Krystexxa Boost Sales March 01, 2022 Horizon Therapeutics plc's (NASDAQ: HZNP) Q4 sales increased 36% Y/Y to $1.014 billion, beating the consensus of $995.87 million. The adjusted gross profit declined... Via Benzinga Horizon Therapeutics: Q4 Earnings Insights March 01, 2022 Horizon Therapeutics (NASDAQ:HZNP) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... Via Benzinga The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution March 01, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine... Via Benzinga Horizon Therapeutics plc Launches #RAREis Representation Program to Elevate Global Rare Disease Equity February 28, 2022 From Horizon Therapeutics plc Via Business Wire The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight February 27, 2022 Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... Via Benzinga Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED) February 23, 2022 From Horizon Therapeutics plc Via Business Wire Insider Buying Detected – Buy This Biotech Now February 23, 2022 Biotech and pharmaceutical research are the hottest growing sectors in the global business market, brought into the public eye by the onset of the COVID-19 pandemic. Via Talk Markets Horizon Therapeutics plc to Present at the Cowen and Company 42nd Annual Health Care Conference February 21, 2022 From Horizon Therapeutics plc Via Business Wire Horizon Therapeutics' Uplinza Reduces Severity of Attacks Associated Spinal Cord Inflammation February 16, 2022 Horizon Therapeutics plc (NASDAQ: HZNP) shared results from a new analysis showing treatment with Uplinza reduced the severity of attacks in people with Neuromyelitis... Via Benzinga Horizon Therapeutics plc Names Sean Clayton Executive Vice President and General Counsel February 16, 2022 From Horizon Therapeutics plc Via Business Wire New Analysis Demonstrates UPLIZNA® (inebilizumab-cdon) Reduces Severity of Attacks Associated with Neuromyelitis Optica Spectrum Disorder (NMOSD) February 16, 2022 From Horizon Therapeutics plc Via Business Wire New Post-Marketing Safety Analysis Shows Rate of Hearing-Related Events Associated with TEPEZZA® (teprotumumab-trbw) Comparable with Clinical Trial Observations February 15, 2022 From Horizon Therapeutics plc Via Business Wire Horizon Therapeutics plc Partners with the Doug the Pug Foundation and Sing Me A Story Foundation to Bring Awareness to Rare Diseases Impacting Children through #RAREis Playlist February 15, 2022 From Horizon Therapeutics plc Via Business Wire Horizon Therapeutics plc Named Title Partner of the Irish Open February 10, 2022 From Horizon Therapeutics plc Via Business Wire Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2021 Financial Results and Host Webcast on March 1, 2022 February 07, 2022 From Horizon Therapeutics plc Via Business Wire Death Cross Looms Over Horizon Therapeutics Investors January 26, 2022 If history is any guide, there may be trouble ahead for shares of Horizon Therapeutics (NASDAQ:HZNP). A so-called "death cross" has formed on its chart and, not surprisingly,... Via Benzinga Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) January 24, 2022 From Horizon Therapeutics plc Via Business Wire 7 of the Top-Rated Pharmaceutical Stocks for Q1 January 18, 2022 As the market begins to shift from high-growth, tech-fueled start-ups, one good long-term growth option is quality pharmaceutical stocks. Via InvestorPlace Horizon Therapeutics plc Submits Supplemental Biologics License for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotrexate for People Living with Uncontrolled Gout January 10, 2022 From Horizon Therapeutics plc Via Business Wire 2022 Could be a Banner Year for Biotech Stocks as per top managers (SPRC, HOTH, NLSP, PSTV, IMMX, GNPX, NRBO) January 06, 2022 Via AB Newswire Horizon Therapeutics plc Announces Significant Expansion of East Coast Research and Development and Technical Operations Capability January 06, 2022 From Horizon Therapeutics plc Via Business Wire < Previous 1 2 ... 10 11 12 13 14 15 16 17 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.